Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer

BACKGROUND: AZD1152, the prodrug for AZD1152-hydroxyquinazoline pyrazol anilide (HQPA), is a selective inhibitor of Aurora B kinase activity. Preclinical evaluation of AZD1152 has been reported in several human cancer models. The potentiality of this compound in combination therapy warrants further...

Descripción completa

Detalles Bibliográficos
Autores principales: Azzariti, A, Bocci, G, Porcelli, L, Fioravanti, A, Sini, P, Simone, G M, Quatrale, A E, Chiarappa, P, Mangia, A, Sebastian, S, Del Bufalo, D, Del Tacca, M, Paradiso, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048212/
https://www.ncbi.nlm.nih.gov/pubmed/21304529
http://dx.doi.org/10.1038/bjc.2011.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048212/
https://www.ncbi.nlm.nih.gov/pubmed/21304529
http://dx.doi.org/10.1038/bjc.2011.21

Ejemplares similares